Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. - Wikidata - awgldk - TriplyDB

Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

http://www.wikidata.org/entity/Q34370297

about

Recombinant human activated protein C for severe sepsis in neonates Human recombinant activated protein C for severe sepsis Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients Human recombinant activated protein C for severe sepsis Co-enrollment of critically ill patients into multiple studies: patterns, predictors and consequences.The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS.Activated protein C in severe acute pancreatitis without sepsis? Not just yet ...Role of human recombinant activated protein C and low dose corticosteroid therapy in sepsis Scientific and clinical challenges in sepsis.Activated protein C in septic shock: a propensity-matched analysis Therapeutic Effects of Treatment with Anti-TLR2 and Anti-TLR4 Monoclonal Antibodies in Polymicrobial Sepsis.Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis.Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated).Patient recruitment into a multicenter randomized clinical trial for kidney disease: report of the focal segmental glomerulosclerosis clinical trial (FSGS CT).Updates on role of human recombinant activated protein C in patients with sepsis and severe sepsis: Changed scenario after PROWESS SHOCK trial.Trials in adult critical care that show increased mortality of the new intervention: Inevitable or preventable mishaps?A dream deferred: the rise and fall of recombinant activated protein C Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center.Early PREdiction of Severe Sepsis (ExPRES-Sepsis) study: protocol for an observational derivation study to discover potential leucocyte cell surface biomarkers Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.Current concept of abdominal sepsis: WSES position paper.Activated protein C in the treatment of acute lung injury and acute respiratory distress syndrome.An update on activated protein C (xigris) in the management of sepsis.Statistical analysis plan of PROWESS SHOCK study.Evidence-based critical care medicine: seeing through a glass darkly.The systemic immune response to pediatric thermal injury.Reply: The Impact of Septic Liver Dysfunction on Long-Term Mortality Must Not Be Neglected.Phosphoinositide-3 kinase gamma activity contributes to sepsis and organ damage by altering neutrophil recruitment.

P2860

Erratum to: Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

P921

Q24200439-01DE13C3-C0CF-4383-A795-23AF579543C5 Q24201123-59822A49-F2E7-49D6-AE5D-42C092D74087 Q24202128-78E5F340-D922-481D-8C9A-2E4F1C806220 Q24235181-1D34BEBA-066F-4305-95FB-345867C72774 Q33750206-FC43C6B6-D98B-497E-8175-BEBDE005EABC Q33751764-3696CFEE-2A7A-4CE8-A06C-7451B6B101B0 Q33974292-969944A0-C72E-46BF-9DB6-07AE3040CFFC Q34130693-F1409731-42D4-4035-86BD-2FB76A330FAA Q34153246-C07AE527-262C-4B69-8BFB-64338E900DFF Q34469113-6BB53514-2A12-4508-AA7D-BADEA4B6BB6C Q34994107-F6CF7689-AE24-4876-9D90-2DE31C54956D Q35559424-1980BE1C-D43F-463B-B43E-F1D9C8604703 Q35683589-5CCC747E-EA6F-4062-9F9F-846C4B232E55 Q35908186-A3CDB4FF-CABC-432F-8CC8-7E23DC552E5C Q36070512-4F7CA99B-DA8B-4349-BA46-00F3F792FEF3 Q36112774-0C65F535-6636-4D56-BC05-696D546674C4 Q36423823-46673441-2C7F-4383-B6C7-397098CA2404 Q36536932-8F08B998-2279-450F-8207-8848D5236B2C Q36614885-BAFF9286-3282-42D0-873D-8BC6F3A2F0A9 Q36902494-E89C3A12-EB64-4EEB-9042-CC775B44FA6F Q36919457-AC67A797-E6C7-4760-9663-F911D1C73006 Q37177606-6742E72B-7957-4F7B-A843-68463FBAD769 Q37354434-85690D34-92FB-4F8D-B38A-BFE6E6A40299 Q37367885-6C53F2AB-1E16-4D21-BF56-355C09B71760 Q37702912-54F607D4-4FBA-4D5E-AD93-4255403B3A9B Q38089190-9B92078E-66FF-47A6-8CAD-1B531927DFCF Q42067556-13E6D182-9408-4E1D-8370-02031C7A00C0 Q42679358-09E61B7F-C233-4F3E-802F-F864382C029C Q48294153-095F254B-7C8F-4C52-B687-E173AA8388E1 Q52726992-F09A9F71-1697-4F6D-8F44-6B565E7506DC Q53787545-811DD642-4D26-467E-81C7-0B11A420FDAA Q54671652-099F423A-8481-42D8-BE26-FF83B4B7D600

P2860

Q46716236-6E725516-2A74-4CDF-B7C7-670659146A74

P921

Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

http://www.wikidata.org/entity/Q34370297

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Design, conduct, analysis and ...... C for persistent septic shock.

@ast

Design, conduct, analysis and ...... C for persistent septic shock.

@en

Design, conduct, analysis and ...... C for persistent septic shock.

@nl

type

label

Design, conduct, analysis and ...... C for persistent septic shock.

@ast

Design, conduct, analysis and ...... C for persistent septic shock.

@en

Design, conduct, analysis and ...... C for persistent septic shock.

@nl

prefLabel

Design, conduct, analysis and ...... C for persistent septic shock.

@ast

Design, conduct, analysis and ...... C for persistent septic shock.

@en

Design, conduct, analysis and ...... C for persistent septic shock.

@nl

P1433

Q34370297-CB1EB9B4-7EA7-49DA-9E3B-06C9EAB26CE3

P1476

Q34370297-EF8684AC-0EC0-41EC-B7F0-D6C02E2AB775

P2093

Q34370297-0663CC3B-8638-47D5-AC59-B23E0F67395F

Q34370297-28C0504C-60CF-42C0-8B7D-5684663631A3

Q34370297-2E9AA72C-C3C7-4DDB-B4B8-AA5BD69CD2D0

Q34370297-58947F58-FA5C-415C-8D1D-FBE4351C39C7

Q34370297-AC911D78-BE5D-41DA-B628-E6ED983AE0C8

Q34370297-DDE6FEE5-D5AA-4061-BC9A-7CFFA7602171

Q34370297-F073BAFF-77D8-44C3-8281-C24271A14010

P2507

Q34370297-8DA28A04-8281-4E5E-AD37-8DDBF932FC94

P2860

Q34370297-1ACFCE25-50AD-4375-9F73-EC0A05CDF4A1

Q34370297-1E7E8F78-F3A1-4E71-9085-9F5A68A6CFB2

Q34370297-2131891C-41BF-4285-8792-C5110EF40740

Q34370297-25E36055-5145-42F7-A24A-0B8BA57107D2

Q34370297-2DC9F3BC-5213-4775-B7A8-7811BA70A5F9

Q34370297-349B6DD2-A73E-416A-9311-FFD0978FF4D4

Q34370297-3614A15E-40C9-478B-A35C-80B08CBAE65F

Q34370297-51DF0BD9-3FF3-4BC4-B11A-F0F83C2726C8

Q34370297-5A3DA4B6-BF5D-4D8B-88A5-ADE538AA58C9

Q34370297-60D0A073-E3B7-4995-8154-1CAAE70C39C1

P2888

Q34370297-19716436-1C41-4CBA-BC58-01264506ECEF

P304

Q34370297-2B032A8B-43FA-42CB-BDE7-D2D9C2777708

P31

Q34370297-076FDEB4-2D29-4532-A8B6-581E94E9E295

P356

Q34370297-C19B398C-E243-497F-87DF-1091CE1466F4

P433

Q34370297-EDB83A4E-7EDF-445F-9DC8-2EA6CD9BC319

P478

Q34370297-65A667D0-0E69-4A75-BA34-00F659DB5E50

P50

Q34370297-5D554DE7-2A71-4BF8-840B-5D454AE27CA6

Q34370297-793451A8-A7D9-4101-826A-6469687F480F

P577

Q34370297-951627DE-DF9E-46C3-9C83-C54EC319FF6A

P5875

Q34370297-BE1D5B2F-615C-43B5-B4F0-4881C8DD40D3

P698

Q34370297-7A4D3005-6DB4-4339-8502-E57456F37980

P921

Q34370297-019CCBCC-90F1-4A6E-AD91-83153538B314

Q34370297-4AEB1049-678F-41EC-A0FA-5D5AACEA41EF

Q34370297-BFD73FB8-A40E-407C-A09A-31D9057CFFAF

P932

Q34370297-CC9EF672-157F-4D2F-B7B0-7EC054511999

P356

S00134-008-1266-6

P1433

Intensive Care Medicine

P1476

Design, conduct, analysis and ...... C for persistent septic shock

@en

P2093

B Taylor Thompson

http://www.w3.org/2001/XMLSchema#string

Bengt Gårdlund

http://www.w3.org/2001/XMLSchema#string

Jean-François Dhainaut

http://www.w3.org/2001/XMLSchema#string

John C Marshall

http://www.w3.org/2001/XMLSchema#string

Philip S Barie

http://www.w3.org/2001/XMLSchema#string

Simon Finfer

http://www.w3.org/2001/XMLSchema#string

V Marco Ranieri

http://www.w3.org/2001/XMLSchema#string

P2507

Erratum to: Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

P2860

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

Human recombinant activated protein C for severe sepsis

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

Severe sepsis epidemiology: sampling, selection, and society

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

The epidemiology of sepsis in the United States from 1979 through 2000

Efficacy and safety of recombinant human activated protein C for severe sepsis

Risks and benefits of activated protein C treatment for severe sepsis.

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?

P2888

s00134-008-1266-6

P304

1935-1947

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00134-008-1266-6

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23303589

http://www.w3.org/2001/XMLSchema#string

P698

18839141

http://www.w3.org/2001/XMLSchema#string

P921

P932

2995439

http://www.w3.org/2001/XMLSchema#string